The use of selumetinib in children with inoperable plexiform neurofibromas

Methods: An open-label Phase 2 trial of selumetinib was conducted to determine objective response rates and assess clinical benefit in patients with plexiform neurofibromas. Children with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromatosis(NF1) receive oral selumetin , twice daily, at a dose of 25mg/m2body surface area, continuous dosing regimen(28day cycle). Volume magnetic resonance imaging and clinical outcome assessment (Pain, quality of life, deficit, and function) were performed at least every four cycles. Children rated tumor pain intensity from 0 (No pain) to 10 (The worst pain imaginable).

Results: Total50children(Median age, 10.2 years; range, 3.5 to < span>17.4)It was registered from 20158month to 20168month. The most common neurofibroma-related symptoms were disfigurement(44cases) and motor dysfunction(33 pan>cases)and pain(26cases). As of2019year3 month29, there are 34patients(68%) had confirmed partial responses, of which 28 patients had durable responses(Continuous≥1years). After 1years of treatment, children's reported tumor pain intensity scores decreased by an average of 2 points, which is considered a clinically meaningful improvement. Additionally, child-reported and parent-reported pain interference with daily functioning(38% and 50%, respectively) and overall health-related quality of life(48%and58%)and strength(56%of patients) Clinically meaningful improvements in functional outcomes were observed in and range of motion (38%of patients). 5 patients discontinued treatment due to toxicity that may be related to selumetinib, and 6 patients experienced disease progression. The most common toxic reactions are nausea, vomiting, or diarrhea; asymptomatic increases in creatine phosphokinase levels; acneiform rash; and paronychia.

Conclusion: In this Phase 2 trial, most children with neurofibromatosis type 1 and inoperable plexiform neurofibromas had durable tumor shrinkage and clinical benefit from selumetinib in the majority of children. There is an original research version of selumetinib overseas, with a retail price of 10 mg 60 tablets 50,000around. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.